Old Web
English
Sign In
Acemap
>
authorDetail
>
Erica C. VanderPorten
Erica C. VanderPorten
Sunesis Pharmaceuticals
PLK1
Signal transduction
Kinase
Polo-like kinase
Chemistry
3
Papers
85
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model
2009
Molecular Cancer Therapeutics
Erica C. VanderPorten
Pietro Taverna
Jennifer N. Hogan
Marcus D. Ballinger
W. Michael Flanagan
Raymond V. Fucini
Show All
Source
Cite
Save
Citations (53)
Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.
2008
Bioorganic & Medicinal Chemistry Letters
Emily J. Hanan
Raymond V. Fucini
Michael J. Romanowski
Robert A. Elling
Willard Lew
Hans E. Purkey
Erica C. VanderPorten
Wenjin Yang
Show All
Source
Cite
Save
Citations (0)
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
2008
Bioorganic & Medicinal Chemistry Letters
Raymond V. Fucini
Emily J. Hanan
Michael J. Romanowski
Robert A. Elling
Willard Lew
Kenneth J. Barr
Jiang Zhu
Joshua C. Yoburn
Yang Liu
Bruce T. Fahr
Junfa Fan
Yafan Lu
Phuongly Pham
Ingrid Choong
Erica C. VanderPorten
Minna Bui
Hans E. Purkey
Marc J. Evanchik
Wenjin Yang
Show All
Source
Cite
Save
Citations (32)
1